Mesothelioma

Orphan Disease with Lethal Outcomes

Mesothelioma is one of the most lethal cancers with a high unmet medical need. Current therapies have limited effect and no therapy has potential for complete cure. There is an urgent need for a more effective treatment that gives hope of survival without significantly impacting quality of life. The most common type, pleural mesothelioma, develops in the lining of the lungs. Peritoneal mesothelioma forms in the peritoneum, the membrane that lines the abdominal cavity. This is the second-most prevalent type.

The most common treatments for mesothelioma are surgery, chemotherapy and radiation. In very early stages of the disease surgery is often the most effective treatment and in some cases can be curative. In later stages there is no therapy that can cure the disease and most treatment options focus on palliative treatments that can help alleviate pain, breathing problems and other symptoms that impact quality of life.

There is a significant unmet medical need in the treatment of mesothelioma for a treatment that not only can prolong overall survival without negatively impacting the quality of life of patients, but also one that may represent a cure for subjects that are in the later stages of the disease. The REIC immune-oncology technology has been demonstrated to have a real potential to be a break through therapy in mesothelioma based on preclinical models. MTG is focused on moving our MTG-201 and MTG-202 products into the clinic to evaluate the potential for this novel therapy to have significant impact in the treatment of patients with mesothelioma.

    • Mesothelioma is a deadly disease with high medical unmet need
    • US/EU incidence is 8000 patients total
    • Overall survival is low for all stages of mesothelioma
  • Stage 1 = 21 months
  • Stage 3 = 16 months
  • Stage 2 = 19 months
  • Stage 4 = 12 months

 

Limited Treatment Options

The only approved drug for mesothelioma is pemetrexed (Alimta), which has limited efficacy and significant toxicity